Opportunities for the use of aerosolized alpha 1-antitrypsin for the treatment of cystic fibrosis.
Cystic fibrosis (CF), the most common lethal genetic disease affecting the white population, owes its morbidity and mortality primarily to the devastating effects of chronic inflammation and infection within the pulmonary airways. It has become increasingly recognized that the host's response to Pseudomonas species and Staphylococcus aureus infection plays a paramount role in CF lung destruction and eventual development of respiratory insufficiency. A massive pulmonary influx of neutrophils, and accompanying excessive levels of neutrophil elastase (NE), can be detected in the bronchoalveolar fluid of even very young children with CF. The excess of NE adversely affects the CF airways by enhancing mucus secretion, directly injuring airway tissues, exacerbating the inflammatory process by attracting more neutrophils, and derailing opsonization and elimination of bacterial pathogens, particularly Pseudomonas aeruginosa. Neutralization of excess NE by delivering supplemental alpha 1-antitrypsin to the airways via aerosolization represents an exciting new potential therapy for CF lung disease.
Allen
E D
ED
Children's Hospital, Ohio State University, Columbus, USA.
D000336:Aerosols; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D019272:Leukocyte Elastase / Q000378:metabolism; D009504:Neutrophils / Q000201:enzymology; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage* / Q000627:therapeutic use
D000336:Aerosols; D000515:alpha 1-Antitrypsin; D019272:Leukocyte Elastase